Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol

Michael R. Rickels, Chengyang Liu, Richard D. Shlansky-Goldberg, Scott A. Soleimanpour, Kumar Vivek, Malek Kamoun, Zaw Min, Eileen Markmann, Maral Palangian, Cornelia Dalton-Bakes, Carissa Fuller, Allen J. Chiou, Clyde F. Barker, Eline T. Luning Prak, Ali Naji

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The Clinical Islet Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet culture, heparinization, and intensive insulin therapy with the same lowdose tacrolimus and sirolimus maintenance immunosuppression as in the Edmonton protocol. To determine whether CIT07 improves engrafted islet β-cells mass, our center measured β-cells secretory capacity from glucose-potentiated arginine tests at days 75 and 365 after transplantation and compared those results with the results previously achieved by our group using the Edmonton protocol and normal subjects. All subjects were insulin free, with CIT07 subjects receiving fewer islet equivalents from a median of one donor compared with two donors for Edmonton protocol subjects. The acute insulin response to glucose-potentiated arginine (AIRpot) was greater in the CIT07 protocol than in the Edmonton protocol and was less in both cohorts than in normal subjects, with similar findings for C-peptide. The CIT07 subjects who completed reassessment at day 365 exhibited increasing AIRpot by trend relative to that of day 75. These data indicate that engrafted islet β-cells mass is markedly improved with the CIT07 protocol, especially given more frequent use of single islet donors. Although several peritransplant differences may have each contributed to this improvement, the lack of deterioration in β-cells secretory capacity over time in the CIT07 protocol suggests that low-dose tacrolimus and sirolimus are not toxic to islets.

Original languageEnglish (US)
Pages (from-to)2890-2897
Number of pages8
JournalDiabetes
Volume62
Issue number8
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Islets of Langerhans Transplantation
Tacrolimus
Sirolimus
Insulin
Islets of Langerhans
Arginine
Glucose
Antilymphocyte Serum
C-Peptide
Poisons
Immunosuppression
Transplantation
Maintenance

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Rickels, M. R., Liu, C., Shlansky-Goldberg, R. D., Soleimanpour, S. A., Vivek, K., Kamoun, M., ... Naji, A. (2013). Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes, 62(8), 2890-2897. https://doi.org/10.2337/db12-1802

Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol. / Rickels, Michael R.; Liu, Chengyang; Shlansky-Goldberg, Richard D.; Soleimanpour, Scott A.; Vivek, Kumar; Kamoun, Malek; Min, Zaw; Markmann, Eileen; Palangian, Maral; Dalton-Bakes, Cornelia; Fuller, Carissa; Chiou, Allen J.; Barker, Clyde F.; Luning Prak, Eline T.; Naji, Ali.

In: Diabetes, Vol. 62, No. 8, 08.2013, p. 2890-2897.

Research output: Contribution to journalArticle

Rickels, MR, Liu, C, Shlansky-Goldberg, RD, Soleimanpour, SA, Vivek, K, Kamoun, M, Min, Z, Markmann, E, Palangian, M, Dalton-Bakes, C, Fuller, C, Chiou, AJ, Barker, CF, Luning Prak, ET & Naji, A 2013, 'Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol', Diabetes, vol. 62, no. 8, pp. 2890-2897. https://doi.org/10.2337/db12-1802
Rickels, Michael R. ; Liu, Chengyang ; Shlansky-Goldberg, Richard D. ; Soleimanpour, Scott A. ; Vivek, Kumar ; Kamoun, Malek ; Min, Zaw ; Markmann, Eileen ; Palangian, Maral ; Dalton-Bakes, Cornelia ; Fuller, Carissa ; Chiou, Allen J. ; Barker, Clyde F. ; Luning Prak, Eline T. ; Naji, Ali. / Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol. In: Diabetes. 2013 ; Vol. 62, No. 8. pp. 2890-2897.
@article{951af4795ae54ca3a11926aeba15b853,
title = "Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol",
abstract = "The Clinical Islet Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet culture, heparinization, and intensive insulin therapy with the same lowdose tacrolimus and sirolimus maintenance immunosuppression as in the Edmonton protocol. To determine whether CIT07 improves engrafted islet β-cells mass, our center measured β-cells secretory capacity from glucose-potentiated arginine tests at days 75 and 365 after transplantation and compared those results with the results previously achieved by our group using the Edmonton protocol and normal subjects. All subjects were insulin free, with CIT07 subjects receiving fewer islet equivalents from a median of one donor compared with two donors for Edmonton protocol subjects. The acute insulin response to glucose-potentiated arginine (AIRpot) was greater in the CIT07 protocol than in the Edmonton protocol and was less in both cohorts than in normal subjects, with similar findings for C-peptide. The CIT07 subjects who completed reassessment at day 365 exhibited increasing AIRpot by trend relative to that of day 75. These data indicate that engrafted islet β-cells mass is markedly improved with the CIT07 protocol, especially given more frequent use of single islet donors. Although several peritransplant differences may have each contributed to this improvement, the lack of deterioration in β-cells secretory capacity over time in the CIT07 protocol suggests that low-dose tacrolimus and sirolimus are not toxic to islets.",
author = "Rickels, {Michael R.} and Chengyang Liu and Shlansky-Goldberg, {Richard D.} and Soleimanpour, {Scott A.} and Kumar Vivek and Malek Kamoun and Zaw Min and Eileen Markmann and Maral Palangian and Cornelia Dalton-Bakes and Carissa Fuller and Chiou, {Allen J.} and Barker, {Clyde F.} and {Luning Prak}, {Eline T.} and Ali Naji",
year = "2013",
month = "8",
doi = "10.2337/db12-1802",
language = "English (US)",
volume = "62",
pages = "2890--2897",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Improvement in β-Cell secretory capacity after human islet transplantation according to the CIT07 protocol

AU - Rickels, Michael R.

AU - Liu, Chengyang

AU - Shlansky-Goldberg, Richard D.

AU - Soleimanpour, Scott A.

AU - Vivek, Kumar

AU - Kamoun, Malek

AU - Min, Zaw

AU - Markmann, Eileen

AU - Palangian, Maral

AU - Dalton-Bakes, Cornelia

AU - Fuller, Carissa

AU - Chiou, Allen J.

AU - Barker, Clyde F.

AU - Luning Prak, Eline T.

AU - Naji, Ali

PY - 2013/8

Y1 - 2013/8

N2 - The Clinical Islet Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet culture, heparinization, and intensive insulin therapy with the same lowdose tacrolimus and sirolimus maintenance immunosuppression as in the Edmonton protocol. To determine whether CIT07 improves engrafted islet β-cells mass, our center measured β-cells secretory capacity from glucose-potentiated arginine tests at days 75 and 365 after transplantation and compared those results with the results previously achieved by our group using the Edmonton protocol and normal subjects. All subjects were insulin free, with CIT07 subjects receiving fewer islet equivalents from a median of one donor compared with two donors for Edmonton protocol subjects. The acute insulin response to glucose-potentiated arginine (AIRpot) was greater in the CIT07 protocol than in the Edmonton protocol and was less in both cohorts than in normal subjects, with similar findings for C-peptide. The CIT07 subjects who completed reassessment at day 365 exhibited increasing AIRpot by trend relative to that of day 75. These data indicate that engrafted islet β-cells mass is markedly improved with the CIT07 protocol, especially given more frequent use of single islet donors. Although several peritransplant differences may have each contributed to this improvement, the lack of deterioration in β-cells secretory capacity over time in the CIT07 protocol suggests that low-dose tacrolimus and sirolimus are not toxic to islets.

AB - The Clinical Islet Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet culture, heparinization, and intensive insulin therapy with the same lowdose tacrolimus and sirolimus maintenance immunosuppression as in the Edmonton protocol. To determine whether CIT07 improves engrafted islet β-cells mass, our center measured β-cells secretory capacity from glucose-potentiated arginine tests at days 75 and 365 after transplantation and compared those results with the results previously achieved by our group using the Edmonton protocol and normal subjects. All subjects were insulin free, with CIT07 subjects receiving fewer islet equivalents from a median of one donor compared with two donors for Edmonton protocol subjects. The acute insulin response to glucose-potentiated arginine (AIRpot) was greater in the CIT07 protocol than in the Edmonton protocol and was less in both cohorts than in normal subjects, with similar findings for C-peptide. The CIT07 subjects who completed reassessment at day 365 exhibited increasing AIRpot by trend relative to that of day 75. These data indicate that engrafted islet β-cells mass is markedly improved with the CIT07 protocol, especially given more frequent use of single islet donors. Although several peritransplant differences may have each contributed to this improvement, the lack of deterioration in β-cells secretory capacity over time in the CIT07 protocol suggests that low-dose tacrolimus and sirolimus are not toxic to islets.

UR - http://www.scopus.com/inward/record.url?scp=84888332284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888332284&partnerID=8YFLogxK

U2 - 10.2337/db12-1802

DO - 10.2337/db12-1802

M3 - Article

VL - 62

SP - 2890

EP - 2897

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 8

ER -